Welcome to our dedicated page for VGAC news (Ticker: VGAC), a resource for investors and traders seeking the latest updates and insights on VGAC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VGAC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VGAC's position in the market.
VG Acquisition Corp. (NYSE: VGAC) announced that its shareholders approved the merger with 23andMe, Inc. at a Special Meeting held on June 10, 2021. Over 87% of votes supported the merger, which is set to finalize on June 16, 2021, pending customary closing conditions. Following the merger, VGAC will be renamed to 23andMe Holding Co., with new shares trading on Nasdaq under the symbol 'ME' starting June 17, 2021. 23andMe is recognized for its consumer genetics services and the world's largest crowdsourced genetic research platform.
VG Acquisition Corp. (NYSE: VGAC) has announced its upcoming extraordinary general meeting of shareholders on June 10, 2021, to vote on the proposed business combination with 23andMe, Inc. The board recommends voting 'FOR' the merger, which is expected to close on June 16, 2021. Upon completion, VGAC will be renamed 23andMe Holding Co., with shares listed on Nasdaq under the ticker symbols 'ME' and 'MEUSW'. Shareholders are urged to vote their shares promptly to ensure representation.
VG Acquisition Corp. received a notice from the NYSE on May 25, 2021, due to its failure to file the Quarterly Report on Form 10-Q for the period ended March 31, 2021. This notice does not immediately affect the trading status of VGAC, which will continue on the NYSE, but it indicates a compliance issue. The company plans to restate previously issued financial statements due to SEC guidelines regarding warrant accounting. The extraordinary general meeting to vote on a proposed business combination with 23andMe is scheduled for June 10, 2021.
VG Acquisition Corp. (NYSE: VGAC) announced its upcoming business combination with 23andMe, Inc., which will lead to its rebranding as 23andMe Holding Co. and a listing on Nasdaq. This transition is set to occur on June 16, 2021, with trading under the new ticker symbol "ME" commencing on June 17, 2021. Existing VGAC shareholders will not need to take action regarding the ticker or exchange change. 23andMe, a leader in consumer genetics, aims to help individuals access and benefit from genetic information, and has multiple FDA authorizations for genetic health risk reports.
VG Acquisition Corp. (NYSE: VGAC) has scheduled an extraordinary general meeting for its shareholders on June 10, 2021, to vote on a proposed business combination with 23andMe, Inc., a consumer genetics company. Shareholders must be on record by May 5, 2021. If approved, the merger will rename VGAC to 23andMe Holding Co., trading under the new ticker symbols ME and ME WS on Nasdaq. Shareholders will receive a definitive proxy statement and are advised to vote promptly to ensure representation.
VG Acquisition Corp. (NYSE: VGAC) has submitted an amended registration statement on Form S-4 regarding its merger with 23andMe, Inc., a consumer genetics firm. The filing includes restated financials for VGAC for the fiscal year 2020, reflecting outstanding warrants as liabilities. 23andMe anticipates revenues between $240 million to $247 million for fiscal 2021, higher than previous forecasts of $218 million. Adjusted EBITDA for their Consumer & Research Services segment is expected to improve significantly, while losses in the Therapeutics segment are projected to remain substantial.
23andMe, Inc. has entered a merger agreement with VG Acquisition Corp. (NYSE: VGAC), aimed at creating a publicly traded entity under the ticker 'ME'. This transaction, valued at approximately $3.5 billion, is expected to close in Q2 2021. The merger will provide 23andMe with up to $984 million in cash to fuel growth initiatives. Sir Richard Branson and Anne Wojcicki will invest $25 million each in the deal. With over 80% of its customers participating in genetic research, 23andMe is positioned to advance personalized healthcare through its extensive genetic database.
VG Acquisition Corp. has filed a Registration Statement on Form S-1 with the SEC for an initial public offering of 40 million units at $10.00 each. Each unit will comprise one share of Class A common stock and one-third of a redeemable warrant. The company aims to list these units on the New York Stock Exchange under the symbol VGAC. Established for merger and acquisition purposes, VG Acquisition Corp. will focus on consumer-facing businesses in the U.S. and Western Europe.
